One major role for liquid biopsy in managing lung cancer metastasis is in the context of leptomeningeal metastasis (LM), which occurs in approximately 3–5% of NSCLC and is more common in EGFR-mutant NSCLC [190,191]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.